Restenosis is inhibited through local delivery of anti-restenotic agents including angiotensin converting enzyme inhibitors; nicotine receptor agonists, agents that increase concentrations of nitric oxide, anti-angiogenic agents, agonists of the TGF-beta receptor; death domain receptor ligands; and thrombin inhibitors. In one embodiment of the invention, the localized delivery is effected through the use of a stent modified for delivery of the agent at the site of injury from balloon angioplasty.

 
Web www.patentalert.com

< Botulinum neurotoxin eluting stent

< Angiogenically effective unit dose of FGF-2 and method of use

> System and methods for imaging within a body lumen

> Method of treating myocardial infarction with PDE-5 inhibitors

~ 00264